Quantum BioPharma Ltd. (NASDAQ: QNTM) has entered a Study Start-Up Agreement (SUA) with the clinical research business of Thermo Fisher Scientific to implement its Phase 2 clinical trial of Lucid-21-302 (Lucid-MS) for multiple sclerosis (MS). The agreement, announced via BioMedWire, initiates formal study start-up activities following FDA clearance to proceed with the trial. Thermo Fisher will support study start-up and related clinical research services through its PPD Clinical Research Business.
The randomized, double-blind, placebo-controlled Phase 2 trial will evaluate the efficacy, safety, and tolerability of Lucid-MS in people with progressive forms of MS using clinical and radiological endpoints. Lucid-MS is an investigational, first-in-class New Chemical Entity designed to provide neuroprotection by inhibiting demyelination through targeting protein arginine deiminase 2 (PAD2), an enzyme implicated in myelin degradation. To view the full press release, visit https://ibn.fm/CZH9U.
This development matters because progressive forms of MS currently have limited treatment options, and Lucid-MS represents a novel approach that could address the underlying mechanism of the disease. Unlike existing therapies that primarily modulate the immune system, Lucid-MS aims to prevent and reverse myelin degradation, which is the hallmark of MS. If successful, it could offer a much-needed therapy for patients with progressive MS, potentially slowing or halting disability progression.
Quantum BioPharma is dedicated to building a portfolio of innovative assets for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of Lucid-MS, a patented new chemical entity shown in preclinical models to prevent and reverse myelin degradation. The latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM.
The agreement with Thermo Fisher, a global leader in clinical research services, lends significant credibility and operational expertise to the trial. Thermo Fisher's PPD business will manage study start-up activities, which include site selection, regulatory submissions, and patient recruitment planning. This collaboration could accelerate the trial's timeline and increase the likelihood of successful execution. For the biotech industry, this partnership exemplifies how established contract research organizations are increasingly integral to advancing novel therapies, especially for complex neurological conditions.
For patients and investors, this news signals progress in a high-unmet-need area. Multiple sclerosis affects millions worldwide, and progressive forms often lead to irreversible disability. A disease-modifying therapy that targets remyelination would be a breakthrough. Quantum BioPharma's shares may see increased attention as the trial advances. The company also retains ownership of 19.84% of Unbuzzd Wellness Inc. (as of March 31, 2026), which markets an OTC product, and holds rights to royalty payments of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products for pharmaceutical and medical uses.
BioMedWire is a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio at IBN, delivering wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. For full terms, see https://www.BioMedWire.com/Disclaimer.
